Thyrocare Technologies Limited has completed the allotment of 3,624 equity shares under its Employee Stock Option Scheme on March 02, 2026. The allotment was approved by the company's Nomination & Remuneration Committee following the exercise of stock options by eligible grantees.

Share Allotment Details

The newly issued equity shares carry a face value of Rs. 10 each and will rank pari passu in all respects with the company's existing equity shares. This means the new shares will have equal rights and privileges as the current shareholding, including voting rights and dividend entitlements.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued, subscribed and paid-up equity share capital:

The total increase in paid-up capital amounts to Rs. 36,240, representing the face value of the 3,624 newly allotted shares.

Regulatory Compliance and Next Steps

Thyrocare Technologies is currently in the process of applying for listing and trading approval of these newly allotted shares with the stock exchanges, specifically the National Stock Exchange of India Limited and BSE Limited. The company is also completing other necessary regulatory procedures as required.

Disclosure and Transparency

In line with regulatory requirements under Regulation 30, the company has made these disclosures available on its official website at investor.thyrocare.com/announcements/. The announcement was signed by Brijesh Kumar, Company Secretary and Compliance Officer, ensuring proper corporate governance protocols were followed.

This Employee Stock Option Scheme allotment reflects the company's commitment to employee participation in its growth and aligns with standard corporate practices for talent retention and motivation.

Thyrocare Technologies Limited has announced an additional capital infusion of USD 4,75,000 in its Tanzanian subsidiary, marking another step in the company's international expansion strategy. The investment, made on February 24, 2026, was executed through subscription to Compulsorily Convertible Irredeemable Preference Shares (CCPS) and is equivalent to INR 4,32,91,500.00.

Investment Details and Structure

The latest investment brings the company's total commitment to its Tanzanian operations to USD 11,50,020, equivalent to INR 10,01,62,414. This represents a significant portion of the Board-approved investment limit of up to INR 15 crores for the subsidiary.

Subsidiary Performance and Structure

Thyrocare Laboratories (Tanzania) Limited operates in the diagnostic and healthcare services sector, aligning with the parent company's core business activities. The subsidiary is a joint venture between Thyrocare Technologies Limited and the Kastipharm Group, comprising Kastipharm Limited, Mr. Anwar Alnoor Kachra and Mr. Joseph Philemon Mgaya.

Shareholding Pattern

The investment maintains Thyrocare Technologies' existing shareholding structure in the Tanzanian entity. The company continues to hold a majority stake in equity shares while maintaining complete ownership of the preference shares.

Strategic Rationale

The capital infusion is specifically designed to facilitate business operations and meet working capital requirements of the Tanzanian subsidiary. The company has indicated that remaining capital infusion will be made in one or more tranches, depending on Thyrocare Tanzania's business requirements. The transaction has been structured as a related party transaction conducted at arm's length, with the company confirming that promoters and promoter groups have no other interests beyond those stated.

Regulatory Compliance

The investment disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in accordance with the SEBI Master Circular dated January 30, 2026. Thyrocare Laboratories (Tanzania) Limited was incorporated in the Republic of Tanzania on September 19, 2023, with Registration Number 168657943.